再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

盘前交易 12-19 04:12:25 EST

26.15

-0.82

-3.04%

最高27.49	最低26.00	成交量63.75万
今开27.18	昨收26.97	日振幅5.51%
总市值28.28亿	流通市值25.82亿	总股本1.08亿
成交额1,686万	换手率0.65%	流通股本9,874万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":26.15,"timestamp":1734555600000,"preClose":26.97,"halted":0,"volume":637461,"delay":0,"floatShares":98741700,"shares":108137154,"eps":-2.77706,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.82,"latestTime":"12-19 04:12:25 EST","open":27.18,"high":27.485,"low":26,"amount":16860460.9734,"amplitude":0.055061,"askPrice":33.65,"askSize":100,"bidPrice":21.48,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.77706,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734618600000},"adr":1,"listingDate":1505880000000,"adjPreClose":26.15,"adrRate":10,"postHourTrading":{"tag":"盘后","latestPrice":26.76,"preClose":26.15,"latestTime":"18:50 EST","volume":47144,"amount":1232887.51,"timestamp":1734565844494},"volumeRatio":0.6865803300995678,"impliedVol":0.5643,"impliedVolPercentile":0.2869},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2492583911","title":"再鼎医药下跌2.19%，报26.38美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492583911","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492583911?lang=zh_cn&edition=full","pubTime":"2024-12-19 03:16","pubTimestamp":1734549411,"startTime":"0","endTime":"0","summary":"12月19日，再鼎医药(ZLAB)盘中下跌2.19%，截至03:16，报26.38美元/股，成交745.72万美元。财务数据显示，截至2024年09月30日，再鼎医药收入总额2.9亿美元，同比增长44.32%；归母净利润-1.75亿美元，同比增长26.66%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/19031646565917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1588","BK4588","BK4531","LU2488822045.USD","ZLAB","BK4548","BK4139","BK1574","09688","BK4526","BK4585","BK1161"],"gpt_icon":0},{"id":"2492973452","title":"港股生物技术板块尾盘走强，歌礼制药(01672.HK)涨超15%，圣诺医药(02257.HK)涨超9%，再鼎医药(09688.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492973452","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492973452?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:31","pubTimestamp":1734507119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["07226","HSCEI","BK4588","BK1515","02257","BK4548","01477","YANG","LU2488822045.USD","BK1574","09688","BK4139","BK4585","BK1191","BK1161","BK4531","BK4526","BK1588","02197","01672","HSTECH","ZLAB"],"gpt_icon":0},{"id":"2492368941","title":"再鼎医药(09688)上涨5.15%，报21.45元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492368941","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492368941?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:43","pubTimestamp":1734486189,"startTime":"0","endTime":"0","summary":"12月18日，再鼎医药(09688)盘中上涨5.15%，截至09:43，报21.45元/股，成交605.45万元。再鼎医药有限公司主要业务是研发和销售针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的创新药物，以满足全球患者的医疗需求。关键经营数据方面，公司以其强大的研发能力和全球化运营策略，致力于成为全球领先的生物制药公司。截至2024年三季报，再鼎医药营业总收入20.32亿元、净利润-12.29亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/18094346520900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09688","ZLAB","BK4531","BK1161","BK4585","BK4139","LU2488822045.USD","BK4588","BK1574","BK4548","BK4526","BK1588"],"gpt_icon":0},{"id":"2492096710","title":"再鼎医药上涨2.1%，报26.73美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492096710","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492096710?lang=zh_cn&edition=full","pubTime":"2024-12-18 00:27","pubTimestamp":1734452866,"startTime":"0","endTime":"0","summary":"12月18日，再鼎医药(ZLAB)盘中上涨2.1%，截至00:27，报26.73美元/股，成交264.77万美元。财务数据显示，截至2024年09月30日，再鼎医药收入总额2.9亿美元，同比增长44.32%；归母净利润-1.75亿美元，同比增长26.66%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/18002746507473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4585","BK4588","BK1588","BK1161","BK4531","BK1574","BK4548","09688","BK4139","BK4526","LU2488822045.USD","ZLAB"],"gpt_icon":0},{"id":"2492934870","title":"再鼎医药(09688)发行800万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492934870","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492934870?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:18","pubTimestamp":1734430708,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2024年12月17日，该公司发行800万股新普通股，由受托人持有，以兑现按先前披露的条款归属及(如适用)行使(1)根据2015，2017及2022年股权激励计划所授出的购股权及(2)根据2017和2022年股权激励计划所授出的非期权奖励。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4139","BK4585","LU2488822045.USD","BK1574","BK4531","BK4588","BK4548","BK1161","09688","BK4526","BK1588","ZLAB"],"gpt_icon":0},{"id":"2490338576","title":"再鼎医药下跌2.1%，报26.59美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490338576","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490338576?lang=zh_cn&edition=full","pubTime":"2024-12-12 23:28","pubTimestamp":1734017333,"startTime":"0","endTime":"0","summary":"12月12日，再鼎医药(ZLAB)盘中下跌2.1%，截至23:28，报26.59美元/股，成交198.01万美元。财务数据显示，截至2024年09月30日，再鼎医药收入总额2.9亿美元，同比增长44.32%；归母净利润-1.75亿美元，同比增长26.66%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/12232846338450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4585","ZLAB","BK1574","LU2488822045.USD","BK4548","BK4139","BK1161","BK4526","BK4531","09688","BK1588","BK4588"],"gpt_icon":0},{"id":"2490821679","title":"再鼎医药(09688)下跌5.08%，报20.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490821679","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490821679?lang=zh_cn&edition=full","pubTime":"2024-12-12 13:14","pubTimestamp":1733980448,"startTime":"0","endTime":"0","summary":"12月12日，再鼎医药(09688)盘中下跌5.08%，截至13:14，报20.55元/股，成交2613.37万元。再鼎医药有限公司主要业务是研发和销售针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的创新药物，以满足全球患者的医疗需求。关键经营数据方面，公司以其强大的研发能力和全球化运营策略，致力于成为全球领先的生物制药公司。截至2024年三季报，再鼎医药营业总收入20.32亿元、净利润-12.29亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/12131446304908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","ZLAB","BK4526","BK4531","BK4548","09688","BK4139","BK4588","BK1574","BK1588","LU2488822045.USD","BK4585"],"gpt_icon":0},{"id":"2490868245","title":"再鼎医药下跌2.02%，报27.17美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490868245","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490868245?lang=zh_cn&edition=full","pubTime":"2024-12-11 22:34","pubTimestamp":1733927694,"startTime":"0","endTime":"0","summary":"12月11日，再鼎医药(ZLAB)开盘下跌2.02%，截至22:34，报27.17美元/股，成交21.16万美元。财务数据显示，截至2024年09月30日，再鼎医药收入总额2.9亿美元，同比增长44.32%；归母净利润-1.75亿美元，同比增长26.66%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/11223446284914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["ZLAB","BK4531","BK1161","09688","BK4588","BK4526","LU2488822045.USD","BK4585","BK1574","BK4139","BK4548","BK1588"],"gpt_icon":0},{"id":"2490722940","title":"南向资金12月10日净卖出再鼎医药2.80万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2490722940","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490722940?lang=zh_cn&edition=full","pubTime":"2024-12-11 09:30","pubTimestamp":1733880623,"startTime":"0","endTime":"0","summary":"12月10日，南向资金减持再鼎医药2.80万股连续3日减持。截止当日收盘，港股通共持有再鼎医药10603.05万股，占流通股9.76%。港股通减持金额前五个股分别为美团-W、小米集团-W、理想汽车-W、药明生物、同程旅行。再鼎医药近5个交易日下跌6.02%，港股通累计增持11.92万股；近20个交易日下跌10.63%，港股通累计增持2193.83万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211093303ab6e1dbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211093303ab6e1dbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB","BK4526","BK4531","BK4548","09688","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2490191000","title":"再鼎医药盘中异动 急速跳水5.57%报27.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490191000","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490191000?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:30","pubTimestamp":1733841058,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时30分，再鼎医药股票出现异动，股价大幅下挫5.57%。截至发稿，该股报27.30美元/股，成交量6727股，换手率0.01%，振幅0.00%。最近的财报数据显示，该股实现营业收入1.02亿美元，净利润-41.67百万美元，每股收益-0.42美元，毛利65.35百万美元，市盈率-9.91倍。机构评级方面，在所有11家参与评级的机构中，82%的券商给予买入建议，18%的券商给予持有建议，无券商给予卖出建议。再鼎医药股票所在的生物技术行业中，整体涨幅为0.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223102984b0baa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223102984b0baa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB","BK4139","BK4531","BK4526","BK4588","BK4585","BK4548"],"gpt_icon":0},{"id":"2490925775","title":"再鼎医药盘中异动 早盘大幅上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490925775","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490925775?lang=zh_cn&edition=full","pubTime":"2024-12-09 22:50","pubTimestamp":1733755811,"startTime":"0","endTime":"0","summary":"北京时间2024年12月09日22时50分，再鼎医药股票出现波动，股价急速拉升5.02%。截至发稿，该股报29.38美元/股，成交量12.9663万股，换手率0.12%，振幅2.52%。机构评级方面，在所有11家参与评级的机构中，82%的券商给予买入建议，18%的券商给予持有建议，无券商给予卖出建议。再鼎医药股票所在的生物技术行业中，整体涨幅为0.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209225011a1e0b298&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209225011a1e0b298&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4139","BK4588","BK4531","ZLAB","BK4585","BK4526"],"gpt_icon":0},{"id":"2489523042","title":"再鼎医药上涨2.11%，报28.59美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489523042","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489523042?lang=zh_cn&edition=full","pubTime":"2024-12-07 00:00","pubTimestamp":1733500805,"startTime":"0","endTime":"0","summary":"12月7日，再鼎医药(ZLAB)盘中上涨2.11%，截至00:00，报28.59美元/股，成交229.25万美元。财务数据显示，截至2024年09月30日，再鼎医药收入总额2.9亿美元，同比增长44.32%；归母净利润-1.75亿美元，同比增长26.66%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/07000046125723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["09688","ZLAB","BK4531","BK4585","BK4139","BK1161","BK4548","BK4588","BK1574","BK1588","BK4526","LU2488822045.USD"],"gpt_icon":0},{"id":"2489177872","title":"港股生物医药股走弱，再鼎医药跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489177872","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489177872?lang=zh_cn&edition=full","pubTime":"2024-12-05 10:03","pubTimestamp":1733364221,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月5日，港股生物医药股走弱，再鼎医药跌超7%，云顶新耀-B跌超5%，康诺亚-B和药明合联跌超3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412053259991619.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412053259991619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK4585","YANG","LU2488822045.USD","HSCEI","07226","BK1574","BK4531","BK4588","BK4548","HSTECH","BK1161","09688","BK4526","BK1588","ZLAB"],"gpt_icon":0},{"id":"2489717131","title":"港股生物医药股集体下跌，再鼎医药(09688.HK)跌超7%，百济神州(06160.HK)、药明合联(02268.HK)跌超2%，药明康德(02359.","url":"https://stock-news.laohu8.com/highlight/detail?id=2489717131","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489717131?lang=zh_cn&edition=full","pubTime":"2024-12-05 09:53","pubTimestamp":1733363616,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1141","09688","BK4531","LU1997245094.SGD","BK1583","LU0708995583.HKD","LU2242644610.SGD","06160","BGNE","HSTECH","LU2488822045.USD","LU1969619763.USD","603259","BK0216","BK1576","BK1161","BK1588","HSCEI","07226","399441","LU1046422090.SGD","BK1574","688235","02359","LU1997245177.USD","BK4505","161726","LU0588546209.SGD","BK1500","BK4588","LU0307460666.USD","BK4504","BK4548","LU0456842615.SGD","LU2125910500.SGD","LU0052750758.USD","BK4139","02268","YANG","BK0239","LU2328871848.SGD","LU2045819591.USD","SG9999014674.SGD","BK4526","BK4535","LU0320764599.SGD","BK4585","ZLAB"],"gpt_icon":0},{"id":"1192163500","title":"港股生物医药股延续跌势，再鼎医药、北海康成-B跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192163500","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192163500?lang=zh_cn&edition=full","pubTime":"2024-12-05 09:47","pubTimestamp":1733363259,"startTime":"0","endTime":"0","summary":"12月5日，港股生物医药股延续跌势，$再鼎医药(09688)$、$北海康成-B(01228)$跌超7%，$云顶新耀-B(01952)$跌超4%，$百济神州(06160)$、$博安生物(06955)$跌超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"36cb6ceabfb3d4ad5fa04288d3b7fa77","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07226","BK4585","BK4588","HSCEI","BK1588","BK1161","BK4531","BK1574","BK4548","399441","09688","161726","01228","BK4139","BK4526","YANG","HSTECH","ZLAB"],"gpt_icon":0},{"id":"2489179658","title":"再鼎医药(09688)下跌6.06%，报21.7元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489179658","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489179658?lang=zh_cn&edition=full","pubTime":"2024-12-05 09:30","pubTimestamp":1733362206,"startTime":"0","endTime":"0","summary":"12月5日，再鼎医药(09688)盘中下跌6.06%，截至09:30，报21.7元/股，成交129.93万元。再鼎医药有限公司主要业务是研发和销售针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的创新药物，以满足全球患者的医疗需求。关键经营数据方面，公司以其强大的研发能力和全球化运营策略，致力于成为全球领先的生物制药公司。截至2024年三季报，再鼎医药营业总收入20.32亿元、净利润-12.29亿元。12月3日，骏利亨德森于2024-12-03减持68.18万股，最新持股数目6512万股，最新持股比例5.99%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/05093046037924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK4526","BK1161","ZLAB","LU2488822045.USD","BK4585","BK4139","09688","BK4531","BK1588","BK4548","BK4588"],"gpt_icon":0},{"id":"2488118525","title":"再鼎医药盘中异动 早盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488118525","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488118525?lang=zh_cn&edition=full","pubTime":"2024-12-04 23:15","pubTimestamp":1733325312,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日23时15分，再鼎医药股票出现波动，股价快速下跌5.04%。截至发稿，该股报28.64美元/股，成交量22.3878万股，换手率0.21%，振幅3.42%。再鼎医药股票所在的生物技术行业中，整体跌幅为0.18%。其相关个股中，Cyclerion Therapeutics, Inc.、Exicure, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Cyclerion Therapeutics, Inc.、Can Fite Biopharma Ltd、Windtree Therapeutics, Inc.较为活跃，换手率分别为2578.44%、231.14%、122.41%，振幅较大的相关个股有Cyclerion Therapeutics, Inc.、Eterna Therapeutics Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 ，振幅分别为237.89%、54.25%、46.67%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204231512971ba319&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204231512971ba319&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4139","BK4588","BK4531","ZLAB","BK4585","BK4526"],"gpt_icon":0},{"id":"2488453960","title":"再鼎医药(09688)授出600股美国存托股份的受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2488453960","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488453960?lang=zh_cn&edition=full","pubTime":"2024-12-03 16:34","pubTimestamp":1733214844,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，于2024年 12月2日(美国东部时间)，公司根据2024年股权激励计划向3名承授人涉及合共600股美国存托股份的受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","BK4548","BK4585","BK1588","BK1574","BK4139","BK4526","ZLAB","BK4588","BK4531","BK1161"],"gpt_icon":0},{"id":"2488950728","title":"再鼎医药股价上涨近5% 肿瘤电场治疗胰腺癌迎突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2488950728","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488950728?lang=zh_cn&edition=full","pubTime":"2024-12-03 10:00","pubTimestamp":1733191200,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　再鼎医药（09688）股价上涨4.89%，现报23.60港元，成交额2420.98万港元。\n　　再鼎医药和Novocure宣布，肿瘤电场治疗关键的3期PANOVA-3研究达到了其主要终点，与对照组相比，在中位总生存期（mOS）上显示出统计学意义上的显著改善。PANOVA-3评估了肿瘤电场治疗联合吉西他滨和白蛋白结合型紫杉醇，用于一线治疗不可切除、局部晚期的胰腺癌。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-03/doc-incycyit1787101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK4526","BK1161","ZLAB","BK4585","BK4139","09688","BK4531","BK1588","BK4548","BK4588"],"gpt_icon":0},{"id":"2488939555","title":"港股异动 | 再鼎医药(09688)涨超4% 肿瘤电场治疗胰腺癌迎突破 3期PANOVA-3研究取得阳性主要结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2488939555","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488939555?lang=zh_cn&edition=full","pubTime":"2024-12-03 09:38","pubTimestamp":1733189899,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超4%，截至发稿，涨4.67%，报23.55港元，成交额1606.69万港元。消息面上，再鼎医药和Novocure宣布，肿瘤电场治疗关键的3期PANOVA-3研究达到了其主要终点，与对照组相比，在中位总生存期上显示出统计学意义上的显著改善。Novocure计划基于PANOVA-3，提交肿瘤电场治疗用于治疗不可切除、局部晚期胰腺癌的注册批准，并计划提交PANOVA-3的数据在即将举行的医学大会上进行公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 再鼎医药(09688)涨超4% 肿瘤电场治疗胰腺癌迎突破 3期PANOVA-3研究取得阳性主要结果","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4139","BK4548","BK1588","BK4526","BK4588","ZLAB","BK4531","BK1161","BK1574","09688"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0372},{"period":"1month","weight":0.0389},{"period":"3month","weight":0.2399},{"period":"6month","weight":0.4082},{"period":"1year","weight":-0.1449},{"period":"ytd","weight":-0.0432}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法，以解决中国市场中大量未满足医疗需求的领域，包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib（ZL-2306）、ZL-2103和ZL-1101等。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.113311},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.022208},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.101183},{"month":4,"riseRate":0.428571,"avgChangeRate":0.026877},{"month":5,"riseRate":0.571429,"avgChangeRate":0.03934},{"month":6,"riseRate":0.428571,"avgChangeRate":0.063316},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.00593},{"month":8,"riseRate":0.714286,"avgChangeRate":0.018507},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.066935},{"month":10,"riseRate":0.5,"avgChangeRate":-0.024776},{"month":11,"riseRate":0.625,"avgChangeRate":0.141461},{"month":12,"riseRate":0.5,"avgChangeRate":-0.01639}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}